Hutchison China MediTech Stock Price, News & Analysis (LON:HCM)

GBX 4,675 -22.50 (-0.48 %)
(As of 12/13/2017 12:12 PM ET)
Previous CloseGBX 4,697.50
Today's RangeGBX 4,624.25 - GBX 4,740
52-Week RangeGBX 2,069.61 - GBX 5,310
Volume3,823 shs
Average Volume13,868 shs
Market Capitalization£4.76 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Hutchison China MediTech (LON:HCM)

Hutchison China MediTech logoHutchison China MediTech Limited (Chi-Med) is a China-based, globally-focused healthcare group. The Company researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. Its Innovation Platform focuses on discovering and developing therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures markets and distributes prescription drugs and consumer health products in China.

Receive HCM News and Ratings via Email

Sign-up to receive the latest news and ratings for HCM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Alternative Medicine
Sub-IndustryN/A
SectorHealthcare
SymbolLON:HCM
CUSIPN/A
Phone+85221213888

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPSGBX 0.16
Net IncomeN/A
Net Margins2.91%
Return on Equity1.80%
Return on Assets2.14%

Miscellaneous

EmployeesN/A
Outstanding Shares66,440,000

Hutchison China MediTech (LON:HCM) Frequently Asked Questions

What is Hutchison China MediTech's stock symbol?

Hutchison China MediTech trades on the London Stock Exchange (LON) under the ticker symbol "HCM."

Where is Hutchison China MediTech's stock going? Where will Hutchison China MediTech's stock price be in 2017?

2 brokerages have issued twelve-month price objectives for Hutchison China MediTech's stock. Their forecasts range from GBX 3,840 to GBX 3,840. On average, they expect Hutchison China MediTech's share price to reach GBX 3,840 in the next twelve months. View Analyst Ratings for Hutchison China MediTech.

Who are some of Hutchison China MediTech's key competitors?

Who are Hutchison China MediTech's key executives?

Hutchison China MediTech's management team includes the folowing people:

  • Simon To, Executive Chairman of the Board (Age 63)
  • Christian Hogg, Chief Executive Officer, Executive Director (Age 49)
  • Chig Fung Cheng, Chief Financial Officer, Executive Director (Age 48)
  • Weiguo Su Ph.D., Executive Director (Age 59)
  • Edith Shih, Company Secretary, Non-Executive Director (Age 65)
  • Dan Eldar, Non-Executive Director (Age 62)
  • Paul Rutherford Carter, Senior Independent Non-Executive Director (Age 56)
  • Karen Jean Ferrante M.D., Non-Executive Independent Director (Age 59)
  • Graeme Allan Jack, Independent Non-Executive Director (Age 66)
  • Shu Kam Mok, Non-Executive Independent Director (Age 57)

How do I buy Hutchison China MediTech stock?

Shares of Hutchison China MediTech and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Hutchison China MediTech's stock price today?

One share of Hutchison China MediTech stock can currently be purchased for approximately GBX 4,710.

How big of a company is Hutchison China MediTech?

Hutchison China MediTech has a market capitalization of £4.76 billion.

How can I contact Hutchison China MediTech?

The company can be reached via phone at +85221213888.


MarketBeat Community Rating for Hutchison China MediTech (HCM)

Community Ranking:  3.9 out of 5 (star star star)
Outperform Votes:  129 (Vote Outperform)
Underperform Votes:  38 (Vote Underperform)
Total Votes:  167
MarketBeat's community ratings are surveys of what our community members think about Hutchison China MediTech and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Hutchison China MediTech (LON:HCM) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: GBX 3,840GBX 3,840GBX 3,840GBX 3,530

Hutchison China MediTech (LON:HCM) Consensus Price Target History

Price Target History for Hutchison China MediTech (LON:HCM)

Hutchison China MediTech (LON:HCM) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
8/29/2017Panmure GordonReiterated RatingBuyGBX 3,840View Rating Details
8/1/2017Beaufort SecuritiesReiterated RatingBuyView Rating Details
4/11/2016Stifel NicolausInitiated CoverageBuyView Rating Details
(Data available from 12/13/2015 forward)

Earnings

Earnings History for Hutchison China MediTech (LON:HCM)


No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Hutchison China MediTech (LON:HCM) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Hutchison China MediTech (LON:HCM)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Hutchison China MediTech (LON HCM) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for Hutchison China MediTech (LON:HCM)

Hutchison China MediTech (LON HCM) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/2/2017Karen Jean FerranteInsiderBuy10,000GBX 3,475£347,500
3/15/2017Paul Rutherford CarterInsiderBuy2,800GBX 2,637£73,836
11/21/2016Michael HowellInsiderSell3,000GBX 1,890£56,700
10/28/2016Michael HowellInsiderSell2,500GBX 1,860£46,500
10/26/2016Michael HowellInsiderSell3,000GBX 1,850£55,500
10/25/2016Michael HowellInsiderSell1,000GBX 1,840£18,400
10/24/2016Michael HowellInsiderSell339GBX 1,825£6,186.75
10/7/2016Michael HowellInsiderSell15,000GBX 1,790£268,500
8/4/2016Nash,ChristopherInsiderBuy42GBX 1,899£797.58
10/20/2015Nash,ChristopherInsiderBuy4,512GBX 2,195£99,038.40
4/21/2015Christopher NashInsiderBuy1,388GBX 1,800£24,984
4/15/2015Simon ToInsiderBuy28,000GBX 1,585£443,800
4/10/2015Simon ToInsiderBuy25,000GBX 1,421.50£355,375
4/7/2015Edith ShihInsiderBuy2,000GBX 1,385£27,700
4/2/2015Simon ToInsiderBuy10,000GBX 1,385£138,500
4/1/2015Edith ShihInsiderBuy15,000GBX 1,365£204,750
3/30/2015Edith ShihInsiderBuy13,000GBX 1,300£169,000
(Data available from 1/1/2013 forward)

Headlines

Hutchison China MediTech (LON HCM) News Headlines

Source:
DateHeadline
Hutchison China MediTech Ltd. breached its 50 day moving average in a Bearish Manner : HCM-GB : December 13, 2017Hutchison China MediTech Ltd. breached its 50 day moving average in a Bearish Manner : HCM-GB : December 13, 2017
finance.yahoo.com - December 13 at 11:25 AM
What You Must Know About Hutchison China MediTech Limited’s (HCM) Return on EquityWhat You Must Know About Hutchison China MediTech Limited’s (HCM) Return on Equity
finance.yahoo.com - November 18 at 6:32 PM
FRUTIGA, a Phase III trial of Fruquintinib - London South East (blog)FRUTIGA, a Phase III trial of Fruquintinib - London South East (blog)
www.lse.co.uk - November 1 at 2:02 AM
Hutchison China MediTech (HCM) Initiates FRUTIGA Phase III Trial of Fruquintinib in Second-Line Gastric Cancer - StreetInsider.comHutchison China MediTech (HCM) Initiates FRUTIGA Phase III Trial of Fruquintinib in Second-Line Gastric Cancer - StreetInsider.com
www.streetinsider.com - November 1 at 2:02 AM
Chi-Med Announces the Closing of US Public Offering of American Depositary Shares (ADSs) Raising Approximately ... - Business Wire (press release)Chi-Med Announces the Closing of US Public Offering of American Depositary Shares (ADSs) Raising Approximately ... - Business Wire (press release)
www.businesswire.com - October 30 at 3:22 PM
Chi-Med Announces the Closing of U.S. Public Offering of American Depositary Shares (ADSs) Raising Approximately US$301.3 Million on the Nasdaq Global Select MarketChi-Med Announces the Closing of U.S. Public Offering of American Depositary Shares (ADSs) Raising Approximately US$301.3 Million on the Nasdaq Global Select Market
finance.yahoo.com - October 30 at 3:22 PM
Chi-Med Announces the Full Exercise of Underwriters Over-allotment Option - Business Wire (press release)Chi-Med Announces the Full Exercise of Underwriters' Over-allotment Option - Business Wire (press release)
www.businesswire.com - October 28 at 6:26 AM
Developments in Chinas Healthcare Industry - PR Newswire (press release)Developments in China's Healthcare Industry - PR Newswire (press release)
www.prnewswire.com - October 28 at 6:26 AM
Hutchison China MediTech (HCM) Plans $262M Offer of ADSs - StreetInsider.comHutchison China MediTech (HCM) Plans $262M Offer of ADSs - StreetInsider.com
www.streetinsider.com - October 26 at 9:57 AM
Hutchison China MediTech (HCM) Prices 9.886M ADS at $26.50/Sh - StreetInsider.comHutchison China MediTech (HCM) Prices 9.886M ADS at $26.50/Sh - StreetInsider.com
www.streetinsider.com - October 26 at 9:57 AM
Chi-Med Announces Pricing of U.S. Public Offering of ADSs Raising US$262 Million on Nasdaq Global Select MarketChi-Med Announces Pricing of U.S. Public Offering of ADSs Raising US$262 Million on Nasdaq Global Select Market
finance.yahoo.com - October 26 at 9:57 AM
Chi-Med Reports Preliminary Phase II data on Fruquintinib Combination in First-Line Lung Cancer - Business Wire (press release)Chi-Med Reports Preliminary Phase II data on Fruquintinib Combination in First-Line Lung Cancer - Business Wire (press release)
www.businesswire.com - October 18 at 1:07 AM
Chi-Med and AstraZeneca’s Savolitinib Shows Encouraging Clinical Activity in Second-Line EGFR Mutation-Positive Lung Cancer with MET-AmplificationChi-Med and AstraZeneca’s Savolitinib Shows Encouraging Clinical Activity in Second-Line EGFR Mutation-Positive Lung Cancer with MET-Amplification
finance.yahoo.com - October 17 at 2:04 AM
Form 6-K Hutchison China MediTech For: Oct 16 - StreetInsider.comForm 6-K Hutchison China MediTech For: Oct 16 - StreetInsider.com
www.streetinsider.com - October 16 at 9:04 PM
Hutchison China MediTech: Appointment of Director - Business Wire (press release)Hutchison China MediTech: Appointment of Director - Business Wire (press release)
www.businesswire.com - October 12 at 5:32 AM
Hutchison China MediTech: Appointment of DirectorHutchison China MediTech: Appointment of Director
finance.yahoo.com - October 12 at 5:32 AM
Edited Transcript of HCM.L earnings conference call or presentation 31-Jul-17 8:00am GMTEdited Transcript of HCM.L earnings conference call or presentation 31-Jul-17 8:00am GMT
finance.yahoo.com - October 4 at 2:38 PM
Hutchison China MediTech Ltd. – Value Analysis (LONDON:HCM) : September 26, 2017Hutchison China MediTech Ltd. – Value Analysis (LONDON:HCM) : September 26, 2017
finance.yahoo.com - September 26 at 4:26 PM
Hutchison China MediTech Ltd. breached its 50 day moving average in a Bearish Manner : HCM-GB : September 25, 2017Hutchison China MediTech Ltd. breached its 50 day moving average in a Bearish Manner : HCM-GB : September 25, 2017
finance.yahoo.com - September 25 at 10:17 AM
Directors Share Dealing - London South East (registration) (blog)Director's Share Dealing - London South East (registration) (blog)
www.lse.co.uk - August 31 at 7:19 PM
Hutchison China MediTech (HCM) Initiates Phase I Clinical Trial of Selective PI3Kδ Inhibitor HMPL-689 in Lymphoma - StreetInsider.comHutchison China MediTech (HCM) Initiates Phase I Clinical Trial of Selective PI3Kδ Inhibitor HMPL-689 in Lymphoma - StreetInsider.com
www.streetinsider.com - August 31 at 7:19 PM
Chi-Med Initiates a Phase I Clinical Trial of Selective PI3Kd Inhibitor HMPL-689 in Lymphoma Patients in ChinaChi-Med Initiates a Phase I Clinical Trial of Selective PI3Kd Inhibitor HMPL-689 in Lymphoma Patients in China
www.nasdaq.com - August 29 at 7:54 PM
Hutchison China Meditech Starts Phase One Trial For Lymphoma TreatmentHutchison China Meditech Starts Phase One Trial For Lymphoma Treatment
www.morningstar.co.uk - August 29 at 7:54 PM
Hutchison China MediTech (HCM) Initiates Phase I Clinical Trial of Selective PI3Kδ Inhibitor HMPL-689 in LymphomaHutchison China MediTech (HCM) Initiates Phase I Clinical Trial of Selective PI3Kδ Inhibitor HMPL-689 in Lymphoma
www.streetinsider.com - August 29 at 7:54 PM
Hutchison China MediTech Limiteds (HCM) "Buy" Rating Reiterated at Panmure GordonHutchison China MediTech Limited's (HCM) "Buy" Rating Reiterated at Panmure Gordon
www.americanbankingnews.com - August 29 at 7:24 AM
Chi-Med Initiates a Phase I Clinical Trial of Selective PI3Kδ Inhibitor HMPL-689 in Lymphoma Patients in ChinaChi-Med Initiates a Phase I Clinical Trial of Selective PI3Kδ Inhibitor HMPL-689 in Lymphoma Patients in China
finance.yahoo.com - August 29 at 5:04 AM
DIRECTOR DEALINGS: Zenith Energy CEO Cattaneo Increases StakeDIRECTOR DEALINGS: Zenith Energy CEO Cattaneo Increases Stake
www.morningstar.co.uk - August 23 at 12:58 AM
DIRECTOR DEALINGS: Hutchison China MediTech Non-Executive Buys ADSsDIRECTOR DEALINGS: Hutchison China MediTech Non-Executive Buys ADSs
www.morningstar.co.uk - August 22 at 7:56 PM
Hutchison China MediTech Ltd. :HCM-GB: Earnings Analysis: For the six months ended June 30, 2017 : August 9, 2017Hutchison China MediTech Ltd. :HCM-GB: Earnings Analysis: For the six months ended June 30, 2017 : August 9, 2017
finance.yahoo.com - August 9 at 12:07 AM
Insider Buying: Hutchison China MediTech Limited (HCM) Insider Purchases 10,000 Shares of StockInsider Buying: Hutchison China MediTech Limited (HCM) Insider Purchases 10,000 Shares of Stock
www.americanbankingnews.com - August 7 at 7:28 AM
Hutchison China MediTech Limiteds (HCM) CEO Christian Hogg on Q2 2017 Results - Earnings Call Transcript - Seeking AlphaHutchison China MediTech Limited's (HCM) CEO Christian Hogg on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 6 at 6:03 PM
Chi-Med Reports 2017 Interim Results and Updates Shareholders ... - Business Wire (press release)Chi-Med Reports 2017 Interim Results and Updates Shareholders ... - Business Wire (press release)
www.businesswire.com - July 31 at 3:15 PM
Hutchison China MediTech Limited (LON:HCM) Set to Announce Earnings on SundayHutchison China MediTech Limited (LON:HCM) Set to Announce Earnings on Sunday
www.americanbankingnews.com - July 23 at 4:26 AM
Hutchison China MediTech Limiteds (LON:HCM) Buy Rating Reaffirmed at Beaufort SecuritiesHutchison China MediTech Limited's (LON:HCM) Buy Rating Reaffirmed at Beaufort Securities
www.americanbankingnews.com - July 1 at 1:50 PM
Chi-Med to Announce 2017 Half-Year Financial Results - Business Wire (press release)Chi-Med to Announce 2017 Half-Year Financial Results - Business Wire (press release)
www.businesswire.com - July 1 at 12:33 AM
Chi-Med and AstraZeneca Initiate SAVOIR, a Global Phase III Trial of Savolitinib in Papillary Renal Cell Carcinoma - Business Wire (press release)Chi-Med and AstraZeneca Initiate SAVOIR, a Global Phase III Trial of Savolitinib in Papillary Renal Cell Carcinoma - Business Wire (press release)
www.businesswire.com - June 29 at 5:01 AM
Chi-Med Highlights Phase III Fruquintinib Data in Oral Presentation at ASCOChi-Med Highlights Phase III Fruquintinib Data in Oral Presentation at ASCO
www.businesswire.com - June 5 at 8:43 PM
Chi-Med (HCM) to Present Clinical Data at ASCO - StreetInsider.comChi-Med (HCM) to Present Clinical Data at ASCO - StreetInsider.com
www.streetinsider.com - May 19 at 10:09 AM
Edison Issues Outlook on Hutchison China MediTech (HCM)Edison Issues Outlook on Hutchison China MediTech (HCM)
www.prnewswire.com - May 11 at 6:14 PM
BRIEF-Hutchison China Meditech Ltd says may offer to sell in one or more offerings ADS representing ordinary sharesBRIEF-Hutchison China Meditech Ltd says may offer to sell in one or more offerings ADS representing ordinary shares
www.reuters.com - April 3 at 1:23 PM
Hutchison China Meditech (HCM) Presents At Deutsche Bank Depositary Receipts Virtual Investor Conference - SlideshowHutchison China Meditech (HCM) Presents At Deutsche Bank Depositary Receipts Virtual Investor Conference - Slideshow
seekingalpha.com - March 24 at 5:43 PM
Chi-Med: Grant of Awards under Long Term Incentive PlanChi-Med: Grant of Awards under Long Term Incentive Plan
au.finance.yahoo.com - March 16 at 3:42 PM
Full Year 2016 Hutchison China MediTech Ltd Earnings Release - 03:00 am ETFull Year 2016 Hutchison China MediTech Ltd Earnings Release - 03:00 am ET
biz.yahoo.com - March 13 at 11:09 AM
Chi-Med Presented Sulfatinib Neuroendocrine Tumors Phase Ib/II Results at the 14th Annual Conference of European Neuroendocrine Tumor SocietyChi-Med Presented Sulfatinib Neuroendocrine Tumors Phase Ib/II Results at the 14th Annual Conference of European Neuroendocrine Tumor Society
uk.finance.yahoo.com - March 10 at 10:14 AM
[$$] Chi-Med eyes global markets after cancer trial success[$$] Chi-Med eyes global markets after cancer trial success
www.ft.com - March 3 at 5:37 PM
Chi-Med Looks Outside Its Comfort Zone - Seeking AlphaChi-Med Looks Outside Its Comfort Zone - Seeking Alpha
seekingalpha.com - February 22 at 5:47 PM
Chi-Med Initiates a Phase II Study of Savolitinib in Pulmonary Sarcomatoid CarcinomaChi-Med Initiates a Phase II Study of Savolitinib in Pulmonary Sarcomatoid Carcinoma
uk.finance.yahoo.com - February 20 at 10:50 AM
Form SC 13G Hutchison China MediTech Filed by: CK Hutchison Holdings LtdForm SC 13G Hutchison China MediTech Filed by: CK Hutchison Holdings Ltd
www.streetinsider.com - February 8 at 6:17 PM
HUTCHISON CHINA MEDITECH LIMITEDHUTCHISON CHINA MEDITECH LIMITED
www.finanznachrichten.de - February 1 at 4:23 AM
Hutchison China MediTech (HCM) Begins Phase 1 Of HMPL-523 Clinical Trials In China On Patients With Hematological MalignanciesHutchison China MediTech (HCM) Begins Phase 1 Of HMPL-523 Clinical Trials In China On Patients With Hematological Malignancies
www.streetinsider.com - January 10 at 4:24 AM

SEC Filings

Hutchison China MediTech (LON:HCM) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Social activity is not available for this stock.

Financials

Financials are not available for this stock.

Chart

Hutchison China MediTech (LON HCM) Stock Chart for Wednesday, December, 13, 2017

Loading chart…

This page was last updated on 12/13/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.